KNSA

Kiniksa Pharmaceuticals, Ltd. [KNSA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

KNSA Stock Summary

Earnings have grown 471.24% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous year and become positive (Yearly statements)

Earnings are expected to fall -69.45% next year

Profit margins (0.79%) are lower than the previous year (0.83%)

Top KNSA Correlated Resources

KNSA

Top 10 Correlated ETFs

KNSA

Top 10 Correlated Stocks

KNSA

In the News

06:57 22 Mar 2023 KNSA

The Top 7 Growth Stocks in Biotech

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

12:48 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023

HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

08:28 22 Mar 2023 KNSA

Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting

Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 10:15 a.m. Eastern Time.

04:01 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference

HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time.

11:17 22 Mar 2023 KNSA

Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.

11:37 22 Mar 2023 KNSA

Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why

Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.

02:45 22 Mar 2023 KNSA

Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.

KNSA Financial details

Company Rating

Buy

Market Cap

795.88M

Income

167.01M

Revenue

211.95M

Book val./share

5.71

Cash/share

2.75

Dividend

Dividend %

Employees

215

Optionable

Shortable

Yes

Earnings

01 May 2023

P/E

4.7

Forward P/E

PEG

-0.23

P/S

3.71

P/B

1.98

P/C

4.12

P/FCF

-144.35

Quick Ratio

4.32

Current Ratio

5.16

Debt / Equity

0.16

LT Debt / Equity

0.01

EPS (TTM)

2.4

EPS next Y

EPS next Q

-0.43

EPS this Y

-214.78%

EPS next Y

EPS next 5Y

-194.01%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

-37.58%

EPS Q/Q

-98.02%

SMA20

-15.38%

SMA50

-23.2%

SMA100

-8.48%

Inst Own

42.92%

Inst Trans

-0.24%

ROA

36%

ROE

59%

ROC

-0.02%

Gross Margin

90%

Oper. Margin

-3%

Profit Margin

79%

Payout

Shs Outstand

70.06M

Shs Float

27.52M

Target Price

52W Range

7.36-17.195

52W High

-33.41%

52W Low

+61.71%

RSI

32.19

Rel Volume

1.04

Avg Volume

374.52K

Volume

390.23K

Perf Week

-5.59%

Perf Month

-20.51%

Perf Quarter

-1.65%

Perf Half Y

6.89%

Beta

-0.079973

Volatility

0.16%, 0.94%

Prev Close

1.8%

Price

11.32

Change

-0.53%

KNSA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0.56	3.17
Net income per share	-3.49	-2.99	-2.61	-2.3	2.64
Operating cash flow per share	-2.74	-2.93	-2.21	-1.84	0.08
Free cash flow per share	-2.92	-2.99	-2.21	-2.14	0.08
Cash per share	10.4	4.32	5.23	2.66	2.75
Book value per share	9.45	4.17	5.04	2.7	5.71
Tangible book value per share	9.45	4.17	5.04	2.42	5.45
Share holders equity per share	9.45	4.17	5.04	2.7	5.71
Interest debt per share	0	0.03	0.11	0.09	0.09
Market cap	829.99M	597.79M	1.09B	807.15M	1.04B
Enterprise value	758.01M	550.86M	985.71M	690.73M	922.55M
P/E ratio	-8.04	-3.69	-6.77	-5.11	5.67
Price to sales ratio	0	0	0	20.94	4.72
POCF ratio	-10.25	-3.77	-8	-6.39	178.98
PFCF ratio	-9.62	-3.7	-7.99	-5.5	182.28
P/B Ratio	2.97	2.65	3.5	4.36	2.62
PTB ratio	2.97	2.65	3.5	4.36	2.62
EV to sales	0	0	0	17.92	4.19
Enterprise value over EBITDA	-7.35	-3.4	-6.41	-4.48	2.58
EV to operating cash flow	-9.36	-3.48	-7.22	-5.47	158.87
EV to free cash flow	-8.78	-3.41	-7.2	-4.71	161.79
Earnings yield	-0.12	-0.27	-0.15	-0.2	0.18
Free cash flow yield	-0.1	-0.27	-0.13	-0.18	0.01
Debt to equity	0.15	0.13	0.12	0.26	0.16
Debt to assets	0.13	0.11	0.11	0.21	0.14
Net debt to EBITDA	0.7	0.29	0.7	0.76	-0.33
Current ratio	7.37	8.68	10.46	4.38	5.16
Interest coverage	0	0	0	0	0
Income quality	0.78	0.98	0.85	0.8	0.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	2.58	0.3
Intangibles to total assets	0	0	0	0.08	0.04
Capex to operating cash flow	0.07	0.02	0	0.16	-0.02
Capex to revenue	0	0	0	-0.53	0
Capex to depreciation	-18.5	-1.55	-0.12	-8.67	-0.04
Stock based compensation to revenue	0	0	0	0.65	0.11
Graham number	27.26	16.76	17.21	11.82	18.43
ROIC	-0.65	-1.08	-1.34	11.28	-0.69
Return on tangible assets	-0.32	-0.64	-0.46	-0.74	0.42
Graham Net	8.96	3.78	4.62	2.03	2.12
Working capital	271.2M	213.8M	301.4M	151.62M	195.99M
Tangible asset value	279.27M	225.42M	311.94M	165.79M	377.9M
Net current asset value	271.05M	212.52M	295.72M	148.68M	179.54M
Invested capital	0	0.01	0.02	0.03	0.01
Average receivables	0	0	0	1.99M	8.32M
Average payables	6.07M	8.31M	3.1M	1.19M	4.88M
Average inventory	0	0	0	1.84M	12.64M
Days sales outstanding	0	0	0	37.74	20.99
Days payables outstanding	0	0	0	74.93	125.93
Days of inventory on hand	0	0	0	147.4	344.34
Receivables turnover	0	0	0	9.67	17.39
Payables turnover	0	0	0	4.87	2.9
Inventory turnover	0	0	0	2.48	1.06
ROE	-0.37	-0.72	-0.52	-0.85	0.46
Capex per share	-0.18	-0.06	0	-0.3	0

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-09-30	2021-12-31	2022-03-31	2022-09-30	2022-12-31
Revenue per share	0.18	0.27	0.47	1.43	0.89
Net income per share	-0.44	-0.53	-0.36	3.23	0.06
Operating cash flow per share	-0.42	-0.27	-0.53	0.89	-0.17
Free cash flow per share	-0.42	-0.28	-0.53	0.89	-0.17
Cash per share	2.92	2.64	2.11	2.89	2.75
Book value per share	3.12	2.68	2.4	5.53	5.71
Tangible book value per share	2.83	2.4	2.13	5.26	5.45
Share holders equity per share	3.12	2.68	2.4	5.53	5.71
Interest debt per share	0.1	0.09	0.08	0.1	0.09
Market cap	782.07M	811.79M	687.22M	891.67M	1.04B
Enterprise value	598.63M	695.37M	629.3M	722.62M	922.55M
P/E ratio	-6.4	-5.59	-6.81	0.99	58.25
Price to sales ratio	64.66	43.31	21.35	8.99	16.8
POCF ratio	-27.43	-42.99	-18.65	14.37	-89.78
PFCF ratio	-27.38	-42.42	-18.65	14.37	-90.03
P/B Ratio	3.65	4.39	4.13	2.32	2.62
PTB ratio	3.65	4.39	4.13	2.32	2.62
EV to sales	49.49	37.1	19.55	7.29	14.91
Enterprise value over EBITDA	-19.95	-19.65	-27.85	15.2	2.62
EV to operating cash flow	-21	-36.82	-17.08	11.65	-79.7
EV to free cash flow	-20.96	-36.34	-17.08	11.65	-79.92
Earnings yield	-0.04	-0.04	-0.04	0.25	0
Free cash flow yield	-0.04	-0.02	-0.05	0.07	-0.01
Debt to equity	0.18	0.26	0.39	0.2	0.16
Debt to assets	0.15	0.21	0.28	0.17	0.14
Net debt to EBITDA	6.11	3.29	2.56	-3.56	-0.33
Current ratio	6.32	4.38	3.95	4.28	5.16
Interest coverage	0	0	-685.85	144.14	0
Income quality	0.93	0.52	1.46	0.28	-2.59
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	1.59	1.46	0.65	0.17	0.23
Intangibles to total assets	0.08	0.08	0.08	0.04	0.04
Capex to operating cash flow	0	0.01	0	0	0.01
Capex to revenue	0	-0.01	0	0	0
Capex to depreciation	-0.08	-0.38	0	-0.04	-0.14
Stock based compensation to revenue	0.51	0.33	0.19	0.06	0.1
Graham number	5.59	5.64	4.44	20.04	2.87
ROIC	0.24	2.6	-0.25	2.08	-1.46
Return on tangible assets	-0.13	-0.17	-0.12	0.51	0.01
Graham Net	2.43	2.02	1.58	2.02	2.12
Working capital	183.09M	151.62M	148.4M	185.32M	195.99M
Tangible asset value	194.55M	165.79M	147.24M	365.51M	377.9M
Net current asset value	178.7M	148.68M	134.04M	165.87M	179.54M
Invested capital	0.03	0.03	0.03	0.02	0.01
Average receivables	2.89M	3.6M	16.71M	0	11.91M
Average payables	2.9M	1.76M	2.63M	0	4.68M
Average inventory	5.99M	4.64M	8.45M	0	18.11M
Days sales outstanding	23.99	19.13	82.31	10.13	18.41
Days payables outstanding	53.64	43.48	24.41	11.44	-115.28
Days of inventory on hand	182.34	85.53	95.41	113.83	-315.21
Receivables turnover	3.75	4.7	1.09	8.88	4.89
Payables turnover	1.68	2.07	3.69	7.87	-0.78
Inventory turnover	0.49	1.05	0.94	0.79	-0.29
ROE	-0.14	-0.2	-0.15	0.58	0.01
Capex per share	0	0	0	0	0

KNSA Frequently Asked Questions

What is Kiniksa Pharmaceuticals, Ltd. stock symbol ?

Kiniksa Pharmaceuticals, Ltd. is a BM stock and trading under the symbol KNSA

What is Kiniksa Pharmaceuticals, Ltd. stock quote today ?

Kiniksa Pharmaceuticals, Ltd. stock price is $11.32 today.

Is Kiniksa Pharmaceuticals, Ltd. stock public?

Yes, Kiniksa Pharmaceuticals, Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 374.52K
Market Capitalization 795.88M
Employee 215
CEO Mr. Sanj K. Patel
Headquarters Hamilton,BM
IPO Date 2018-05-24
Website https://www.kiniksa.com

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.